NCT07416539

Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

A Phase 1a, Single-Blind, Randomized Comparative Clinical Trial Evaluating the Impact of Vaccine Formulation on the Safety and Immunogenicity of the COV2 Vaccine in Healthy Adults

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Rokote Laboratories Finland Oy · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein. Participants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28. This trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response.

Conditions

• COVID - 19
• SARS CoV-2

Interventions

Type	Name	Description
BIOLOGICAL	COVID-19 Vaccines	COV2 vaccine given in formulation A in 2 doses as a nasal spray, 28 days between each dose.
BIOLOGICAL	COVID-19 Vaccines	COV2 vaccine given in formulation B in 2 doses as a nasal spray, 28 days between each dose.

Timeline

• Start date: 2026-02-10
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2026-02-18
• Last updated: 2026-02-20

Locations

1 site across 1 country: Finland